论文部分内容阅读
美《医学世界新闻》第20卷第25期(1979年)报道:在美国癌症学会观察干扰素,能否有助于晚期非恶性淋巴瘤、多发性骨髓瘤,黑色素瘤和乳癌病人的治疗之后已经过一年,干扰素仍被认为在临床应用中是有前途的,这是在沃德利(Wadley)分子医学研究所主办的有关干扰素的3天国际会议上宣布的。在肿瘤学家格特曼(Jordan U.Gutter-man)的建议下,美国癌症协会在10个中心对150名病人试用了干扰素。安德森医院和休斯敦肿瘤研究所里38名癌症病人中,21人在接受人白细胞干扰素后得以缓解。格特曼每日给病人肌内注射3百万至9百万单位干扰素,为期28～56天,结果17名晚期乳癌妇女中有7人、10名多发性骨髓瘤病人
U.S.Medical World News, Vol. 20, No. 25 (1979): Observed at the American Cancer Society whether treatment of advanced non-malignant lymphomas, multiple myeloma, melanoma, and breast cancer patients can be helpful. After a year, interferon is still considered to be promising in clinical applications. This was announced at the 3-day international conference on interferon organized by the Wadley Institute of Molecular Medicine. On the advice of oncologist Dr. U. Gutter-man, the American Cancer Society tested interferon in 150 patients in 10 centers. Of the 38 cancer patients in the Anderson Hospital and the Houston Cancer Institute, 21 were relieved after receiving human leukocyte interferon. Goodman daily intramuscular injection of 3 to 9 million units of interferon for 28 to 56 days, resulting in 7 out of 17 women with advanced breast cancer and 10 patients with multiple myeloma